VC: VC Table headline



VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Radius
Cambridge, MA

$57.5M
Second

Second MPM Capital and The Wellcome Trust

Radius is aiming to advance its lead bone anabolic therapy for osteoporosis into Phase II trials.

Sangart
San Diego

$50M
Sixth

Leucadia National Corporation

The money will be used to advance two large-scale Phase III clinical trials of Sangart's lead product candidate, Hemospan.

Syndax
The Woodlands, TX

$40M
First

First Domain Associates and MPM Capital

Syndax is developing cancer therapies.

Aerovance
Berkely, CA

$32M
Third

Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & Co.

The money will be used to advance the asthma drug Aerovant into Phase IIb, scheduled to begin later this year

Company NameNitec Pharma
Switzerland

$26M
Second

NGN Capital Atlas Venture and Global Life Science Ventures

Much of the money is budgeted to advance its therapy for rheumatoid arthritis.

Amira
San Diego

$25M
Second

Novo

Amira is developing new therapies for inflammatory diseases.

Surface Logix
Boston

$20M
Fourth

Fourth Venrock Associates, ARCH Venture Partners, CW Group, HBM BioVentures and Unilever Technology Ventures

The developer has programs in cardiovascular, metabolic, inflammatory and fibrotic diseases.

Egalet
Denmark

$19.27M
Second

Vaekstfonden Life Science Ventures

Egalet has been using its technology for orally-released therapies to develop a pipeline of drugs for pain and cardiovascular uses.

Axial Biotech
Salt Lake City

$15.3M
Second

Johnson & Johnson Development Corporation

The funds raised in this financing will be used to accelerate Axial Biotech's product development efforts and to prepare for the launch of its scoliosis genetic test late next year.

Protemix
San Diego

$14.5M
First

Novartis Venture Fund and NovaQuest

Proceeds from the financing will be used to advance the clinical development of Protemix's lead product, PX811019

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.